Compare Pfizer Inc (PFE) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs TJX Companies Inc — how do they compare? Pfizer Inc trades at $27.68 (market cap $158.34B), while TJX Companies Inc trades at $126.54 (market cap $138.73B). The key difference: Pfizer Inc and TJX Companies Inc are close in size by market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | TJX | |
|---|---|---|
Market Cap | $158.34B | $138.73B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $168.41 |
52-Week Low | $23.60 | $126.10 |
Enterprise Value | $209.83B | $147.04B |
Dividend Yield | 6.19% | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
TJX Companies trades at $128.91, down 2.4% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company reported consistent earnings beats in recent quarters with Q2 2026 EPS of $1.22 exceeding the $1.19 estimate. Revenue growth remains robust, climbing from $48.5B in 2022 to $56.4B in 2025, while net margins improved to 8.63%. Recent news highlights TJX's expansion plans, raising its global store target to 7,500 locations.
The investment outlook remains positive given strong analyst support (84.6% buy ratings) and a $169 consensus price target representing 31% upside. However, near-term technical weakness and valuation concerns present risks. The stock's current P/E of 23.87 appears reasonable given the company's 62% ROE and consistent execution, though competitive pressures in off-price retail warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
